A series of poor decisions led to the FDA granting accelerated approval for aducanumab, despite insufficient evidence that it benefits patients. While the drug effectively reduces amyloid levels, the crucial link between this reduction and actual patient health improvements remains unproven. This decision sparked significant debate within the scientific community, highlighting the risks of prioritizing expediency over comprehensive evidence.
